The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- Neurodegeneration
- 6
Filter Results (173)
-
Research Grant, 2015Phase IB Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A in Those Who Participated in the AFF008 Program
Promising Outcomes of Original Grant:
Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease (PD), and its reduction is expected to positively modify... -
Target Validation, 2015Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression
Study Rationale:
A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s... -
Target Validation, 2015Synapsin III: A Novel Therapeutic Target for Parkinson’s Disease
Objective/Rationale:
In Parkinson’s disease (PD) accumulation of alpha-synuclein at striatal synapses, the neuronal sites of dopamine release, is believed to trigger cell degeneration. We have found... -
Research Grant Supplement, 2015The Influence of Bacterial Amyloid on Alpha-synuclein Misfolding in a Pre-clinical Model Supplement
Promising Outcomes of Original Grant:
We hypothesized that that deposits of the Parkinson’s disease-associated protein alpha-synuclein in gut and brain neurons are caused by exposure to proteins of... -
Research Grant, 2014PARK14-dependent SOCE and Sporadic Parkinson’s Disease
Objective/Rationale:
Mutations in the PARK14 gene are associated with Parkinson’s disease (PD), but its role in idiopathic PD is presently unknown. Recently we identified a role of PARK14... -
Rapid Response Innovation Awards, 2014GSNOR Inhibition for Treatment of Parkinson’s Disease
Study Rationale:
Parkinson’s disease may be driven by inflammation and toxic, reactive products from oxygen metabolism. SAJE Pharma’s drugs target an enzyme called s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.